Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease

Dittmann, M.; Johnson, D. M.; Rapp, M.; Coppi, A.; Isa, F.; Ajithdoss, D.; Fulton, B. O.; Basu, R.; Kania, A. K.; Pascal, K. E.; LeDesma, R.; Ehrlich, G.; Rafique, A.; Marzec, V.; Yuan, J.; Liu, R.; Alfson, K.; Moir-Savitz, T.; Gray, S.; Ippolito, G.; Hallam, C.; Patterson, J.; Baum, A.; Mas Casullo, V.; Copin, R.; Kulkarni, V.; Franklin, M. C.; Kyratsous, C. A.; Orengo, J. M.

doi:10.64898/2026.10.13.758840

Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.13.758840

Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease

View original source ↗Export metadata ↓

Abstract

The 2026 outbreak of Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo and Uganda has created an urgent need for treatments for BDBV disease, yet the only FDA-approved ebolavirus therapeutics, the monoclonal antibody (mAb) cocktail Inmazeb and the mAb Ebanga, are indicated for Zaire ebolavirus (EBOV). Maftivimab (REGN3479), the most potent neutralizing component of Inmazeb, targets ebolavirus species GPs broadly; however, how it engages BDBV GP, whether it neutralizes BDBV-2026, and whether it protects against BDBV disease in vivo are unknown. Here we show that Maftivimab binds to BDBV-2007 GP with high affinity and potently neutralizes pseudoviruses carrying GP from a 2007 reference strain and the 2026 outbreak lineage. Additionally, a cryo-electron microscopy structure of Maftivimab Fab bound to trimeric BDBV-2007 GP superimposes closely on the EBOV GP:Maftivimab complex; importantly, all GP contact residues are conserved between the 2007 and 2026 BDBV sequences. Finally, in cynomolgus macaques challenged with BDBV-2007, a single dose of Maftivimab monotherapy given 7 days after infection, after the onset of clinical disease, rescued 6 of 6 animals, whereas 5 of 6 placebo-treated animals succumbed. These findings demonstrate that Maftivimab neutralizes BDBV, binds to its epitope on BDBV GP and is efficacious in treating established BDBV disease in the macaque model. The data support its evaluation in clinical trials during the ongoing or future outbreak.

Explore related subjects

immunology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Dittmann, M., Johnson, D. M., Rapp, M., Coppi, A., Isa, F., Ajithdoss, D., Fulton, B. O., Basu, R., Kania, A. K., Pascal, K. E., LeDesma, R., Ehrlich, G., Rafique, A., Marzec, V., Yuan, J., Liu, R., Alfson, K., Moir-Savitz, T., Gray, S., Ippolito, G., Hallam, C., Patterson, J., Baum, A., Mas Casullo, V., Copin, R., Kulkarni, V., Franklin, M. C., Kyratsous, C. A., Orengo, J. M.. 2026-10-14. Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease. https://doi.org/10.64898/2026.10.13.758840

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Type 1 immunity linked to CMV exposure improves long-term survival in sepsis without shock

Dysregulated immune responses are at the core of sepsis pathology and can drive both acute organ dysfunction and long-term morbidity and mortality. To better understand the association between specific immune histories, perturbations and sepsis outcomes, we combined immune phenotyping, functional cytokine production assays and antibody repertoire profiling. While sepsis immune profiles were highly heterogeneous, we identified a strong association between the frequency of CXCR3-expressing CD4 memory T cells at time of enrollment and six-month survival in sepsis without shock. Surprisingly, the same population was linked to improved organ function trajectories in septic shock patients but did not influence six-month survival, highlighting the importance of considering physiological states to define immune predictors. Finally, phage display profiling revealed that these Th1 cells were generally expanded in CMV-seropositive individuals, suggesting that previous and latent infections may modulate sepsis outcomes.

immunology↗

bioRxiv2026

Innate Immune Dysregulation Precedes Clinical Onset in Neuromyelitis Optica

Neuromyelitis optica spectrum disorder (NMOSD) is a disabling inflammatory central nervous system (CNS) disease characterized by pathogenic aquaporin 4 (AQP4) autoantibodies. The biological events that precede clinical onset remain unknown. In a unique longitudinal NMOSD cohort from the U.S. Department of Defense Serum Repository, with samples collected up to 24 years before onset, we applied discovery proteomics (~5,400 proteins), pan-viral antibody profiling (VirScan), and in silico analyses to characterize preclinical NMOSD versus matched healthy controls. Innate immune activation, particularly CXCL1 elevation, was the dominant immunological feature of preclinical NMOSD, preceding onset by ~12.7 years. AQP4-IgG was detectable more than 3 years before onset, while CNS injury markers increased only after disease manifestation. VirScan identified enhanced CMV-specific antibody reactivity following AQP4- IgG seroconversion, and network analyses revealed interactions between NMOSD-associated and CMV-derived proteins. Together, these findings establish a novel multi-hit model of NMOSD, with implications for understanding antibody-mediated autoimmunity more broadly.

immunology↗

bioRxiv2026

IL-2 and CD40L can establish and sustain a human B cell-mediated immune regulatory network

B cells can control inflammation, but the factors governing B cell-mediated immune regulatory network remain unclear. We report that IL-2/CD40L enable class-switched memory (CSM) B cells to acquire an immunosuppressive phenotype characterized by the expression of surface TIGIT as well as multiple other inhibitory receptors (PD-1, LAG-3, GITR, CD39, and CTLA-4) and soluble molecules (IL-10, granzyme B, and IL-35). TIGIT+ CSM B cells expressing functional CCR9 exhibit significant defects in total immunoglobulin secretion, while preserving IgA2 secretion. Furthermore, IL-2/CD40L-induced ex vivo-generated TIGIT+ CSM B cells suppress human T cell-mediated inflammation in a xenogeneic mouse model of acute graft-versus-host disease, while promoting IL-10-producing regulatory T cell (Treg) response. These findings identify IL-2/CD40L as key drivers of a B cell-mediated immune regulatory network, especially by generating TIGIT+ CSM B cells that can further promote Treg response. This study supports the development of TIGIT+ B cell-based therapy models for inflammatory diseases.

immunology↗